Current FDA-approved kinase inhibitors cause diverse adverse effects, some of which are due to 2 8 the mechanism-independent effects of these drugs. Identifying these mechanism-independent 2 9 interactions could improve drug safety and support drug repurposing. We have developed 3 0 "iDTPnd", a computational approach for large-scale discovery of novel targets for known drugs.
0 1
We did not do redundancy reduction between the positive and the negative dataset. As structural 1 0 2 databases are growing exponentially, the number of drugs to which the method can be applied is protein structures which are the targets of more than 60% marketed drugs, we had 328 structures (https://blanco.biomol.uci.edu/mpstruc/). Therefore, we expect our method to be applicable for 1 0 9
broader set of studies going forward. assigned to the left out protein. Constructing the structural signature: The flowchart of our method is shown in 1 1 8 Supplementary Fig 1. Briefly, CASTp webserver was used to extract the pocket that the drug 1 1 9
binds to [39] , referred to as the 'bound pocket' from here on. Sequence order-independent 1 2 0 alignment was used to find the pocket similar to the bound pocket [40, 41] using the distance 1 2 1 function described below. We extracted the conserved (positive and negative) structural Sequence Score = 1-(Sequence Similarity / Best Sequence Similarity) Our method is not sensitive to the exact value of α as long as it is close to 1. The α can be 1 3 0 adjusted according to empirical insight from the data. For this study we use α = 1.2. RMSD is the aligned positions. Every position in the signature is present in at least 50% of the structures. To 1 3 5 achieve a minimalistic structural signature, preservation ratio cutoff is increased if the number of 1 3 6 atoms in the signature is more than 100. While combining the positive and the negative structural signatures, predicted targets are those that have better positive score than the negative one 1 3 8
(Score positive -Score negative < 0).
3 9
MicroScale Thermophoresis: The predicted protein targets HLA-A (Acris Antibodies GmbH: (also extracted from [11]) dubbed "negative signature" using the same procedure as the positive 1 7 8 dataset ( Figure 1 (d-f) ). The pocket that was most similar to the bound pocket from each 1 7 9
structure was used to construct the negative signature. This is similar to the well-established known targets with 52% sensitivity (ranging between 42% -68%) and 55% specificity (ranging 1 9 0 between 50% -59%) in 5-fold cross-validation tests. To evaluate the effect of sequence 1 9 1 similarity in the dataset we constructed a baseline model using sequence similarity (see Methods). Using this baseline sequence model, we could only assign 47% of the proteins to According to our data set, the 5 kinase inhibitors chosen in this study interact with 26% (on predictions can be determined using combinatorics and is very small (<1%). In order to identify new drug targets, we extracted the top 3 pockets (largest volume) of 2 1 7 structures deposited in the Protein Data Bank (PDB) using CASTp [39] . We then aligned the validation tests, a protein is considered a potential target only when one of the pockets has 2 2 0
Score positive -Score negative < 0. We then predicted the strength of the interaction between the drug docking methods, we provide a significance measure for these binding scores. The significance 2 2 4 measure is calculated by comparing the binding scores obtained for potential targets of a drug 2 2 5
with the binding scores of 100 random protein structures with the respective drug. The size of the 2 2 6 random sample can be increased for improved statistical significance at the cost of significant enables us to identify more promiscuous compounds such as gefitinib, where even the targets 2 3 0 with most favorable docking score have an unfavorable significance measure (meaning that the 2 3 1 compound is unusually sticky and is interacting with many proteins with high probability).
3 2
Therefore, we exclude gefitinib from our study. Table 2 gives the top 10 predicted targets of consists of two steps. The first step requires identifying all protein targets for which Score positive -2 3 6
Score negative < 0. In the second step, we sort in ascending order with respect to the docking score. which are reported to be within 100 nM and 1 μ M [11]), indicating that these interactions with ERα is a nuclear receptor that is activated by estrogen and is important for hormone/DNA approved drug for breast cancer treatment [53] . ERα was ranked 3 rd , 9 th and 10 th among the 2 8 0 predicted targets for sunitinib, pazopanib and Dasatinib respectively in our results. We used 2 8 1
MST to test our predictions in vitro. We also included sorafenib and imatinib in our experiments 2 8 2 to test our false negative rate. predicted at detectable levels in our setup, we found that imatinib bound to ERα with a Kd of 2 8 6 335±114 nM even though ERα was not predicted as a target for imatinib in our results 2 8 7
suggesting that iDTPnd does have some false negatives. In support, a recent case study reported developed resistance to endocrine therapy [54] . Although the focus of the study was on the 2 9 0 mechanism-independent relationship between pazopanib and fibroblast growth factor receptors, direct interaction between dasatinib and ERα. Sunitinib has also been reported to inhibit tumor 2 9 5 growth in breast cancer cells [56] . Further studies are required to comprehensively understand 2 9 6 the pharmaceutical effects of these interactions. Dasatinib, imatinib and sorafenib were found to interact with CDK2 with a Kd of 2.2±0.9 μ M, 3 1 1 6.6±2.9 μ M, 9.1±2.7 μ M respectively (Figure 4 ). We found that pazopanib also interacts with 3 1 2 CDK2 with a Kd of 4.7±1.4 μ M even though CDK2 was not predicted as a target for pazopanib 3 1 3 in our results (Figure 4 ). While sunitinib did not interact with CDK2 as predicted at detectable that this modulation is a direct result of the interaction between CDK2 and dasatinib. We observed that MHC Class I (HLA-A/HLA-B) proteins were predicted as potential targets for bind the presented peptide and on recognition of an infected state, initiate an immune response. Peptide binding to the MHC Class I proteins is the most selective step in the antigen presentation peptide binding region ( Figure 5 ), which is one of the two pockets identified by the structural this study directly interact with many HLA alleles (13-31 out of 33) ( metabolism, FDA tests these interactions before approving a drug. We found that the predicted 3 5 7
interactions were indeed reported in the FDA Orange Books ( by randomly sampled drugs and potential targets) are pertinent to the improvement of drug target Herein, we propose "iDTPnd": a computational method for large-scale discovery of novel targets Sunitinib respectively but did not give any results for Pazopanib. We analyzed the Top50 and 3 9 7
Top200 targets for each drug from Dr. PRODIS and DTINet for the known proteins that contain 3 9 8 a kinase domain and interact with the respective drugs (Table 6 ). These results represent the 3 9 9 apparent sensitivity of Dr. PRODIS and DTINet, which is much lower than the sensitivity of 4 0 0
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